/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

F

François‐Clément Bidard

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

542

Papers

16.3K

Citations

66

h-index

187

i10-index

François‐Clément Bidard is an academic researcher from Inserm. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Advanced Breast Cancer Therapies & Cancer Cells and Metastasis. The author has an h-index of 66, co-authored 461 publications.

ORCID: 0000-0001-5932-8949

Research Topics

Cancer Genomics and Diagnostics Advanced Breast Cancer Therapies Cancer Cells and Metastasis Breast Cancer Treatment Studies HER2/EGFR in Cancer Research

Papers by this author

works

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

2022 · Journal of Clinical Oncology · 643 citations

https://doi.org/10.1200/jco.22.00338

François‐Clément Bidard Virginia Kaklamani Patrick Neven Guillermo Streich

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

2014 · Annals of Oncology · 373 citations

https://doi.org/10.1093/annonc/mdu239

Leticia De Mattos‐Arruda Britta Weigelt Javier Cortés Helen Won

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

2022 · The Lancet Oncology · 291 citations

https://doi.org/10.1016/s1470-2045(22)00555-1

François‐Clément Bidard Anne‐Claire Hardy‐Bessard Florence Dalenc

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

2022 · The Lancet Oncology · 291 citations

https://doi.org/10.1016/s1470-2045(22)00555-1

François‐Clément Bidard Anne‐Claire Hardy‐Bessard Florence Dalenc

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

2016 · Annals of Oncology · 278 citations

https://doi.org/10.1093/annonc/mdw067

Hervé Bonnefoi Thomas Grellety Olivier Trédan Mahasti Saghatchian

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

2012 · Cancer and Metastasis Reviews · 235 citations

https://doi.org/10.1007/s10555-012-9398-0

François‐Clément Bidard Tanja Fehm Michail Ignatiadis Jeffrey B. Smerage

Research topics

topics

Cancer Genomics and Diagnostics

Advanced Breast Cancer Therapies

Cancer Cells and Metastasis

Breast Cancer Treatment Studies

HER2/EGFR in Cancer Research

Chat about Author

Papers

Chat

Click to start Chat